Ovarian actions of resveratrol. (August 2015)

• Record Type: Journal Article
• Authors: Ortega, Israel; Duleba, Antoni J.
• Other Names: Vang Ole guestEditor.; Pezzuto John M. guestEditor.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1348(2015)
• Page Start: 86
• Page End: 96
• Publication Date: 2015-08
• Subjects: granulosa cells -- hyperandrogenism -- PCOS -- resveratrol -- steroidogenesis -- theca‐interstitial cells; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.12875
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract : Resveratrol, a natural polyphenol found in grapes, berries, and medicinal plants, exhibits antioxidant and anti‐inflammatory activities and has been proposed to be a longevity‐prolonging agent. There is also growing evidence that resveratrol has cardioprotective properties and beneficial effects on both glucose and lipid metabolism. Recently, several studies have examined the use of resveratrol as a therapeutic agent to treat numerous pathological and metabolic disorders. Herein, we present insights into the mechanisms of action, biological effects, and current evidence of actions of resveratrol on the ovary. In vitro, resveratrol inhibits proliferation and androgen production by theca‐interstitial cells. Resveratrol also exerts a cytostatic, but not cytotoxic, effect on granulosa cells, while decreasing aromatization and vascular endothelial growth factor expression. In vivo, resveratrol treatment reduced the size of adipocytes and improved estrus cyclicity in the previously acyclic rat model of polycystic ovary syndrome (PCOS). In addition, resveratrol increased the ovarian follicular reserve and prolonged the ovarian life span in rats. Taken together, resveratrol emerges as a potential therapeutic agent to treat conditions associated with androgen excess, such as PCOS. The efficacy of resveratrol in the treatment of gynecological conditions requires further investigation.